Expert endocrinologists explore the pathophysiology of type 1 diabetes (T1D) and delve into screening and staging processes. They discuss strategies for delaying its onset and provide insight into the future of T1D management.
EP. 1: Risk Factors and Triggers for Type 1 Diabetes (T1D)
Schafer Boeder, MD, discusses the incidence of type 1 diabetes, highlighting risk factors such as age and family history.
EP. 6: Clinical Signs Leading to Diagnostic Testing for T1D
Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.
EP. 8: Interpreting T1D Antibody Test Results
Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.
EP. 10: Efficacy of Teplizumab in Clinical Trials
Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.
EP. 11: Long-Term Monitoring of Teplizumab in T1D
Expert endocrinologists discuss implementing long-term monitoring of patients being treated with teplizumab for type 1 diabetes and review the PROTECT study for patients who are newly diagnosed with T1D.
EP. 12: Improving Access to Teplizumab and Future Treatments of T1D
Experts in endocrinology share challenges of patient access to type 1 diabetes treatment as well as resources to combat these challenges.
EP. 13: Investigational Approaches for Treating T1D
Schafer Boeder, MD, and Egils K. Bogdanovics, MD, share approaches to prevention, preservation, and replacement therapies for the treatment of T1D.